drugset / Trial / NCT00989274

Clinical Trial to Evaluate the Immunogenicity and Safety of the Vaccine Against Influenza A/H1N1

NCT00989274 ↗

RandomizedParallel-groupQuadruple-blindPrevention

Summary

In agreement with the World Organization of the Health (WHO), during the annual epidemics of influenza they become infected between 10-20 % of the total population, appearing from a feverish disease up to leading to the hospitalization and in some cases to the death. To unpredictable intervals and due to the nature of the virus, this one can acquire new genes of others virus of the influenza that they concern birds or porks, of it it turns out to be a new virus with a completely new subtype of IT (HE,SHE) HAS and NA, and if this one is transmitted efficiently of person-to-person can cause a pandemic. This phenomenon has been the one that has given place to the appearance of a new causative virus of the outbreak of influenza humanizes in Mexico (A/México/2009 (H1N1)), and in agreement to official Mexican numbers(figures), until August 13 there have been brought(reported) a whole of 18,861 cases and 163 deaths. The measure of the most effective control against the influenza constitutes it the vaccine, by what study becomes imperative to possess (to rely on) a vaccine against the new virus To (H1N1) East is relevant, due to the level of response of alert to a level 6 (pandemic) that has passed the World Organization of the Health (WHO).

Timeline

Start
2010-06
Primary completion
2010-06
Completion
2010-07

Outcome

Outcome not reported

Stopped: “Late approval by the Secretariat of Health, and expiration of vaccine”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Vaccine Sanofi A(H1N1) Vaccine 7.5 ug —
Comparator Vaccine Sanofi A(H1N1) Vaccine 15 ug —
Comparator Vaccine trivalent Vaccine — —

Indications